Rankings
▼
Calendar
MLYS Q3 2025 Earnings — Mineralys Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
MLYS
Mineralys Therapeutics, Inc.
$2B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$15,000
Operating Income
-$41M
Net Income
-$37M
EPS (Diluted)
$-0.52
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$29M
Free Cash Flow
-$29M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$600M
Total Liabilities
$24M
Stockholders' Equity
$576M
Cash & Equivalents
$218M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$15,000
$0
—
Operating Income
-$41M
-$60M
+31.6%
Net Income
-$37M
-$56M
+34.5%
← Q2 2025
All Quarters